scholarly journals Treatment of Allergic Rhinitis with Ectoine Containing Nasal Spray and Eye Drops in Comparison with Azelastine Containing Nasal Spray and Eye Drops or with Cromoglycic Acid Containing Nasal Spray

2014 ◽  
Vol 2014 ◽  
pp. 1-13 ◽  
Author(s):  
Nina Werkhäuser ◽  
Andreas Bilstein ◽  
Uwe Sonnemann
Keyword(s):  
Allergic Rhinitis ◽  
Side Effects ◽  
Nasal Spray ◽  
Treatment Strategies ◽  
Common Disease ◽  
Eye Drops ◽  
Treatment Regimens ◽  
Ocular Symptoms ◽  
New Treatment ◽  
Design And Methods

Objectives. Allergic rhinitis is a common disease with increasing prevalence and high impact on economic burden and comorbidities. As treatment with pharmacological drugs is not always satisfactory due to side effects and incomplete efficacy, alternative treatment strategies are needed. Ectoine is an osmolyte with membrane stabilizing and inflammation reducing capacities. Nasal spray and eye drops containing ectoine are promising new treatment regimens for allergic rhinitis sufferers. Design and Methods. The current two noninterventional trials evaluated the efficacy and safety of ectoine containing nasal spray and eye drops for treating allergic rhinitis in comparison with either azelastine or cromoglycic acid containing products. Nasal and ocular symptom developments as well as judgment of tolerability and efficacy were assessed both by investigators and patients over a time period of one to two weeks. Results. Both trials confirmed that ectoine containing products reduced nasal and ocular symptoms in allergic rhinitis patients. Results clearly demonstrated good safety profiles of the ectoine products comparable to those of azelastine and even better to those of cromoglycate products. Conclusion. Ectoine containing nasal spray and eye drops are interesting new treatment strategies for sufferers of allergic rhinitis, combining both good efficacy and absence of side effects.

scholarly journals Meta-Analysis of the Efficacy of Ectoine Nasal Spray in Patients with Allergic Rhinoconjunctivitis

2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
Andrea Eichel ◽  
Andreas Bilstein ◽  
Nina Werkhäuser ◽  
Ralph Mösges
Keyword(s):  
Nasal Obstruction ◽  
Nasal Spray ◽  
Meta Analysis ◽  
Area Under The Curve ◽  
Eye Drops ◽  
Ocular Symptoms ◽  
Patient Diary ◽  
Eye Symptoms ◽  
Meta Analyses ◽  
Design And Methods

Objectives. The meta-analysis aims to investigate the efficacy of ectoine nasal spray and eye drops in the treatment of allergic rhinitis and rhinoconjunctivitis symptoms. Design and Methods. This meta-analysis is based on yet unpublished data of four studies. Both nasal and eye symptoms were documented in patient diary cards. All scales were transformed into a 4-point scale: 0 = no, 1 = mild, 2 = moderate, and 3 = severe symptoms. Each symptom was analysed individually in a meta-analysis of the area under the curve values as well as in a meta-analysis of pre- and posttreatment comparison. Results. After seven days of treatment with ectoine nasal spray both nasal and ocular symptoms decreased significantly. A strong reduction of symptom severity was shown for the parameters rhinorrhoea (31.76% reduction) and nasal obstruction (29.94% reduction). Furthermore, the meta-analyses of individual symptoms to investigate the strength of effect after seven days of medication intake showed significant improvement for nasal obstruction, rhinorrhoea, nasal itching, sneezing, itching of eyes, and redness of eyes. The improvement of the symptom nasal obstruction was associated with a strong effect 0.53 (±0.26). Conclusions. The ectoine nasal spray and eye drops seem to be equally effective as guideline-recommended medication in the treatment of rhinoconjunctivitis symptoms.

scholarly journals Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis

2011 ◽  
Vol 49 (3) ◽  
pp. 272-280
Author(s):  
T. Schafer ◽  
M. Schnoor ◽  
M. Wagenmann ◽  
L. Klimek ◽  
C. Bachert
Keyword(s):  
Allergic Rhinitis ◽  
Side Effects ◽  
Clinical Decision Making ◽  
Therapeutic Index ◽  
Clinical Decision ◽  
Efficacy And Safety ◽  
Medline Search ◽  
Intranasal Corticosteroids ◽  
Ocular Symptoms ◽  
Safety Outcomes

Background: Intranasal corticosteroids (INS) are the first line treatment for allergic rhinitis (AR). To guide clinical decision-making, we created a therapeutic index (TIX) for INS reflecting efficacy and safety. Methods: A Medline search (1966 to June 2009) was carried out to identify all placebo-controlled randomized trials, and observational reports for safety issues, with Dexamethasone, Budesonide (BUD), Fluticasone propionate (FP), Fluticasone furoate (FF), Flunisolide, Mometasone furoate (MF), Triamcinolone (TRIAM), and Beclomethasone dipropionate (BDP) as treatment for AR. Data on three efficacy (nasal symptoms, ocular symptoms, global assessment) and three safety outcomes (epistaxis, growth, systemic ocular effects) were extracted. Meta analyses were performed for each INS and outcome and results were categorised into scores by quartiles. Scores of the three efficacy and safety outcomes were summed up to create summation scores for efficacy (ES) and side effects (AES), respectively with a maximum of 9 points. The TIX was then defined as the ratio of ES and AES. Results: Data of 84 studies were extracted. Based on availability of data, a TIX was calculated for 6 substances. BUD showed the highest efficacy score followed by MF and TRIAM. The lowest scores for side effects were achieved by MF and TRIAM followed by FP. These findings resulted in TIX scores of 7 and 5 for MF and TRIAM, respectively, indicating a high efficacy and low potential of adverse events. Medium scores were reached by BUD and FP and lower scores by BDP and FF. Conclusion: Although safety and efficacy is proven for all available INS by multiple studies, the systematic aggregation and analysis of data allows for a differentiated summary on clinically important features.

scholarly journals Faster onset of action with topical levocabastine than with oral cetirizine

1995 ◽  
Vol 4 (7) ◽  
pp. S5-S10 ◽  
Author(s):  
Michel A. Drouin ◽  
William H. Yang ◽  
Frederick Horak
Keyword(s):  
Nasal Spray ◽  
Therapeutic Efficacy ◽  
Allergic Rhinoconjunctivitis ◽  
Eye Drops ◽  
Open Label ◽  
Onset Of Action ◽  
Study Drug Administration ◽  
Treatment Groups ◽  
Ocular Symptoms ◽  
Nasal Symptoms

This international multicentre, open-label, parallel-group trial was undertaken to compare the therapeutic efficacy and tolerability of topical levocabastine and oral cetirizine in patients with perennial allergic rhinoconjunctivitis, with particular reference to the comparative onset of action of the two drugs. A total of 207 patients were randomized to receive either levocabastine nasal spray (0.5 mg/ml, two sprays in each nostril twice daily) plus levocabastine eye drops as required (0.5 mg/ml, one drop in each eye twice daily p.r.n.) or cetirizine orally (10 mg once daily) with a treatment duration of 2 weeks. Onset of action was found to be significantly more rapid with levocabastine than with cetirizine for both nasal and ocular symptoms (p < 0.001). Within 15 min of study drug administration, 36% of levocabastine-treated patients reported relief from nasal symptoms and 32% relief from ocular symptoms compared with 10% and 17% of patients on cetirizine, respectively. At 1 h, the percentages of patients reporting relief were 76% and 38% for nasal symptoms, and 81% and 48% for ocular symptoms in the levocabastine and cetirizine treatment groups, respectively. At 8 h there were no differences between the two treatments. Overall therapeutic efficacy was found to be comparable in the two treatment groups over the 2-week study period with no significant intergroup differences in symptom severity or global therapeutic efficacy. Both drugs were well tolerated with no significant differences in the incidence or type of adverse reactions between the two groups. In conclusion, levocabastine eye drops and nasal spray are as effective and well tolerated as oral cetirizine for the treatment of perennial allergic rhinoconjunctivitis with the advantage of a significantly faster onset of action for both nasal and ocular symptoms.

Efficacy of Fluticasone Propionate Nasal Spray on Ocular Symptoms Relief in Seasonal Allergic Rhinitis

2015 ◽  
Vol 135 (2) ◽  
pp. AB271
Author(s):  
Paul H. Ratner ◽  
Julius H. Van Bavel ◽  
Dale E. Mohar ◽  
Robert L. Jacobs ◽  
Frank Hampel ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Fluticasone Propionate ◽  
Nasal Spray ◽  
Seasonal Allergic Rhinitis ◽  
Ocular Symptoms

scholarly journals Endometrial Cancer Patients: A Cohort Previous to Changes in Tumour Behaviour and Treatment Strategies

2011 ◽  
Vol 2011 ◽  
pp. 1-6
Author(s):  
F. K. L. Tournois ◽  
H. J. M. M. Mertens
Keyword(s):  
Endometrial Cancer ◽  
Cancer Treatment ◽  
Treatment Strategies ◽  
Patient Characteristics ◽  
National Guidelines ◽  
Treatment Regimens ◽  
Time Period ◽  
New Treatment ◽  
Figo Classification

Nowadays, the incidence of endometrial cancer is rising, especially of high-grade endometrial tumours. Recently, the FIGO classification of endometrial cancer has changed worldwide. Besides that, treatment strategies are changing. The purpose of this study was to analyse the adherence to the national guidelines of cancer treatment and to analyse patterns of disease relapse and survival. We focused on a group of patients () with endometrial cancer, in a time period in which new treatment strategies are not yet completely implemented. Because of multiple upcoming changes in patient characteristics, tumour classification, as well as treatment regimens, a more heterogeneous cohort of patients diagnosed with endometrial cancer will appear. From now on, all those changes will have their effects on the followup of conventional endometrial cancer treatment. In our opinion, it is, therefore, valuable to have the current, more homogenous, cohort clearly described.

scholarly journals Evaluating the Protective Properties of a Xyloglucan-Based Nasal Spray in a Mouse Model of Allergic Rhinitis

2021 ◽  
Vol 22 (19) ◽  
pp. 10472
Author(s):  
Marika Lanza ◽  
Giovanna Casili ◽  
Alessia Filippone ◽  
Michela Campolo ◽  
Irene Paterniti ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Side Effects ◽  
Nasal Spray ◽  
Standard Of Care ◽  
Similar Efficacy ◽  
Specific Ige ◽  
Ar Model ◽  
Concomitant Treatment ◽  
Junction Protein ◽  
Significant Efficacy

A breached nasal epithelial barrier plays an important role in driving allergic rhinitis (AR). Corticosteroids remain the standard of care (SoC) but come with side effects, thus alternative safe and effective treatments able to avoid inflammation and restore barrier integrity are needed. The aim of the present study is to evaluate the barrier-forming capacity of a xyloglucan-based nasal spray (XG) and compare its efficacy to several SoC treatments (corticosteroid spray, oral mast-cell stabilizer and oral antihistamine) in reducing allergic responses in addition to its effect when concomitantly administered with an antihistamine. An ovalbumin (OVA)-induced mouse AR model was used. XG shows a significant efficacy in reducing histological damage in AR mice; improves nasal rubbing and histamine-induced hyper-responsiveness. Total and OVA-specific IgE as well as pro-inflammatory cytokines are significantly reduced compared to OVA challenged-mice, with im-proved efficacy when used as an add-on treatment. However, XG reduces mucous secreting cells (PAS-positive) and mucin mRNA expression similar to the corticosteroid-treated mice. XG-spray maintains tight junction protein expression (ZO-1) and conversely decreases HDAC1 significantly; the latter being highly expressed in AR patients. Moreover, the concomitant treatment showed in all of the endpoints a similar efficacy to the corticosteroids. This innovative approach may represent a novel therapeutic strategy for nasal respiratory diseases like AR, reducing undesirable side effects and improving the quality of life in patients.

New treatment strategies for allergic rhinitis utilizing the oral mucosa

2012 ◽  
Vol 12 ◽  
pp. 7-13
Author(s):  
Y. Okamoto ◽  
A. Inamine ◽  
S. Yonekura ◽  
T. Fujimura ◽  
S. Horiguchi
Keyword(s):  
Allergic Rhinitis ◽  
Oral Mucosa ◽  
Treatment Strategies ◽  
New Treatment
Sign in / Sign up

Export Citation Format

Share Document